Jago Grahak Jago

Edit Template

Bank liable for wrong done by its employees: SC orders bank to compensate man

May 06,2024 In a recent ruling, the Supreme Court has held the District Cooperative Bank in Varanasi accountable for service lapses, affirming its vicarious liability for the actions of its employees . The apex court directed the bank to compensate a man with Rs 25,000 nearly three decades after he was wrongly denied access to his fixed deposit. A bench comprising Justices P S Narasimha and Aravind Kumar upheld the decision of the district consumer forum from 1997, which had initially granted compensation to the aggrieved individual. The National Consumer Disputes Redressal Commission’s (NCDRC) contrary ruling was overturned by the apex court. The case revolves around the non-release of fixed deposit receipts totaling Rs 1,60,000 by the District Cooperative Bank in Varanasi. The petitioner alleged that the bank had unlawfully prevented him from withdrawing his funds. The district consumer forum, upon review, ordered the bank to refund the amount along with 15% interest, and an additional Rs 25,000 in damages. The Supreme Court, in its judgment, emphasized, “It is seen from the record that the district forum was satisfied that the appellant had, in fact, handed over Rs 1,60,000 to the bank’s officials. This is evidenced from the bank’s ledger.” The court noted the establishment of an inquiry committee that recommended criminal proceedings against certain officials, which the bank had duly pursued. Additionally, it acknowledged the periodic renewal of fixed deposit receipts, thereby affirming the bank’s vicarious liability for its employees’ actions. Source: Economic TImes

Bank liable for wrong done by its employees: SC orders bank to compensate man Read More »

Airbnb, Goa host fined ₹10,000 by consumer court for accident involving infant

May 09,2024 The Consumer Disputes Redressal Commission in Chandigarh has fined the homestay marketplace Airbnb and one of its hosts ₹10,000 after a six-month-old child was accidentally injured while the property was being cleaned. The Commission President Pawanjit Singh and members Surjeet Kaur and Suresh Kumar Sardana noted an email exchange between the complainants and Airbnb, where Airbnb and the caretaker admitted to the incident and apologised. The emails from the accused clearly admit the incident on March 6, 2022, when the complainant’s six-month-old daughter, wrapped in a blanket, fell while the room was being cleaned by the caretaker, and the accused also apologised, the May 2 order stated. The commission directed both Airbnb and the property caretaker to pay ₹5,000 to the complainant as compensation, along with an additional ₹5,000 for litigation costs. The development comes after the bench heard a complaint from the child’s mother. Source: CNBCTV

Airbnb, Goa host fined ₹10,000 by consumer court for accident involving infant Read More »

Information sought under RTI Act cannot be denied citing difficulty in collating it: Delhi HC

May 09,2024 Difficulty in collating information cannot be the grounds for denying details sought under the Right to Information Act, the Delhi High Court has observed. In a judgment on May 2, Justice Subramonium Prasad said that a public authority cannot justify denying any information to an applicant under the Act by claiming that the details were not available in a single place and that would take time to collate it. “Efforts have to be made by the department to collate the information and then give it to the respondent,” the court held. Prasad observed that the objective of the Right to Information Act was to ensure transparency in the functioning of government departments and that this mandate cannot be obstructed by state governments. The judgment came on a petition filed by the Delhi government against an order of the Central Information Commission. The commission had asked the state government to provide information under the Act to applicant Prabhjot Singh Dhillon regarding actions taken by the education department against government teachers for conducting private tuitions. The Delhi government told the High Court that it could not provide such information for unaided schools as it they did not fall within its jurisdiction, reported Bar and Bench. It also said that private unaided schools do not fall under the purview of the Right to Information Act. The state said that the vigilance arm of the Department of Education had not issued any directions to maintain data on cases of misconduct by government teachers. The High Court rejected the state’s petition. Prasad remarked that information regarding actions taken against teachers of aided schools would be available with the department, though not in one place, and could be provided to Dhillon. “[The Delhi School Education Rules, 1973] stipulates that if a School intends to take a major penalty against a teacher then the approval of the Director of Education is necessary and without such an approval any action of major penalty cannot be imposed on the teacher,” the court held. “Therefore, information related to teachers of private unaided schools can be collated from the records of major punishment imposed by such schools.” Source: Scroll.in

Information sought under RTI Act cannot be denied citing difficulty in collating it: Delhi HC Read More »

Despite SC intensifying its focus on misleading ads, amendment to curb fake ads by drug cos delayed since 2020

Apr 30,2024 As Supreme Court intensifies its focus on companies against misleading advertisements, amendment to strengthen the Drug and Magic Remedies (Objectionable Advertisements) Act, 1954 have been in stuck with the Union Health Ministry since February 2020, reported ToI. In response to an RTI application seeking the status of the amendment, the ministry responded last month that the matter was still “pending”. The Ministry had formed the committee through an order back on December 10, 2019. It included representatives from Ayush Ministry, Consumer Affairs department, Information and Broadcasting Ministry and a few state drug controllers. The draft amendment bill was made public for comments on February 3, 2020, just when Covid struck. The committee that drafted the amendment bill had recommended the DMR(OA) (Amendment) Bill 2020 “in order to giving the sharper teeth (sic) and to keep pace with the changing time and technology”. The main changes proposed were to enhance punishment and to increase the number of conditions for which ads for drugs claiming to diagnose, cure, mitigate, treat, or prevent would be prohibited from 54 to 78. The penalty was to increase from “imprisonment which may extend to six months or with fine, or with both” for first conviction to “imprisonment which may extend to two years and fine up to ten lakh rupees”. For subsequent convictions, penalty under DMRA is “imprisonment which may extend to one year, or with fine, or with both”. The amendment proposed to increase it to imprisonment up to five years and fine up to fifty lakh rupees. All comments received were compiled by the CDSCO (Central Drugs Standard Control Organisation) and sent it to the ministry by the end of June 2020. A draft cabinet note was put up before the health minister in November 2020 and a slide presentation on the draft was made by the CDSCO on the request of the ministry. The next month, it was suggested that the draft be circulated among all states as they would be the ones to implement it. The file circulated some more till Covid put a stop to it. It was next picked up in September 2022 when it was decided that a meeting ought to be held with the drug controller general of India on the matter. From the RTI reply recently, it appears that there has been no progress after that. The DMRA amendment was initiated on the recommendation of a Parliamentary standing committee, whose report tabled in March 2018 stated that “it is the need of the hour to strictly monitor and regulate the misleading advertisements for promoting the sale of AYUSH medicine”. Unlike the Drugs and Cosmetics Act, 1940, DMRA brings within its ambit medicines of all systems including Ayurvedic drugs. This is why many of the complaints against Patanjali’s drugs were filed under DMRA as they claimed to cure/treat diseases listed under the DMRA. “Despite the parliament committee’s recommendation to enact a strong law to prevent misleading and illegal ads, it is clear from the file noting that I obtained through RTI, that there is no file movement since 2022. I complained to the Prime Minister’s office and even after direction from the PMO, they are sitting on it,” said Dr Babu, an ophthalmologist and RTI activist, who has filed several complaints against Patanjali ads for violating DMRA. Source: Economic Times

Despite SC intensifying its focus on misleading ads, amendment to curb fake ads by drug cos delayed since 2020 Read More »

Aggrieved home buyer: Should you file a case in RERA or civil court, which works better for you?

May 06,2024 Regardless of whether you have purchased a flat, bungalow, or a house, you have the right to file a case if you have any grievances where you feel that the RERA Act may have been violated. The Real Estate Regulatory Authority (RERA) Act was enacted for this very purpose — to solve home buyers ‘ grievances and promote a healthy real estate market in India. It is important to consider that in some situations, taking legal action through civil court may be the best course of action or the only option available. So, the question is how you should decide which way to move. We tell you how to choose. As per an ANAROCK report (released in December 2023), which cited data from the Ministry of Housing & Urban Affairs (MoHUA), 1,16,300 cases of homebuyers’ disputes since 2016 till November 28, 2023, have been resolved by RERA courts across India. One of the criteria for filing a case under RERA is that the respective home/flat/bungalow etc., must be registered under the RERA Act. Registration under the RERA Act is mandatory for every real estate project with more than eight apartments or a size of more than 500 square metres. “Complaints can be filed by home buyers under Section 31 of the Real Estate (Regulation and Development) Act, 2016, either with the Real Estate Regulatory Authority or the adjudicating officer. Cases can be against promoters, allottees and/or real estate agents for any violation or contravention of the provisions mentioned under the RERA Act such as delay in possession, demand for advance payment above 10% without execution and registration of agreement for sale, structural defects and others,” says Heena Chheda, Partner, Economic Laws Practice, a law firm. Chheda says that the RERA Adjudicating Officer is empowered to determine the compensation payable in matters pertaining to Sections 12, 14, 18 and 19 of the RERA Act. “The RERA Authority is empowered to adjudicate the dispute pertaining to the violation or contravention of the provisions of the RERA Act or the rules and regulations made thereunder,” she says. “During the pre-RERA period, the industry was often seen as less transparent, with buyers frequently facing delays in project deliveries and discrepancies with amenities as promised and those that were finally delivered. Post-RERA, the industry has seen significant improvements in transparency and accountability. RERA has played a crucial role in formalizing the real estate sector while also promoting fairness and transparency in real estate deals. This has not only benefited buyers but has also provided genuine developers a level playing field,” says Prashant Sharma, President, National Real Estate Development Council (NAREDCO) Maharashtra. Legal experts say that aggrieved home buyers file a case in RERA first and then approach the RERA Appellate Tribunal and then the high court and then ultimately the Supreme Court if their dispute is not solved. “As per Section 79 of the RERA Act, Civil Courts shall not have any jurisdiction to entertain any suit or proceeding concerning matters that the Real Estate Regulatory Authority (RERA), adjudicating officer or Appellate Tribunal is empowered to determine under the RERA Act,” says Shabala Shinde, Partner, Grant Thornton Bharat, a tax and business consultancy firm. The RERA Act provisions are applicable in addition to existing legal Acts, which means all other Acts can be made applicable while deciding a case under the RERA Act. “The intention is to avoid duplication of legal processes and ensure consistency in resolving real estate related disputes. However, Section 88 does specify that provisions of the RERA Act shall apply in addition to and not in derogation of other applicable laws,” says Shinde. Source: Economic Times

Aggrieved home buyer: Should you file a case in RERA or civil court, which works better for you? Read More »

Feeling wronged as a consumer? Know the process and timeline of filing a complaint in a consumer court

May 04,2024 The Consumer Protection Act, 2019 safeguards consumers’ rights and covers all goods and services of all public, private, or cooperative sectors, except those exempted by the central government. This Act provides consumers with a platform for grievance redressal and compensation. As per the Act, individuals who feel wronged after purchasing goods or services can seek help from consumer commissions to resolve their issues. “Any person who has purchased goods or availed any services for its personal use could file a case in the consumer forum if the goods so purchased are defective, or the services suffer from any deficiency or shortcoming,” says Abhay Pratap Singh, Partner, GnS Legal, a law firm. “Consumer should not tolerate the inconvenience or wrong done to them and file appropriate complaints to ensure the same is not repeated by the unscrupulous traders to them and others in the society,” says Vijay Kumar Makyam, a distinguished lawyer who is currently serving as a member of District Consumer Redressal Commission, Medak at Sangareddy. “A prescribed fee is required to be paid depending on the consideration paid by the consumer. Moreover, ensure that the complaint is filed within two years from the date the cause of action arose. Additionally, don’t forget to serve a personal or legal notice to the opposite party before filing the case,” says Subramanium. Another application needs to be filed if the consumer commission’s order is not complied with. “If the final order is not complied with in time, file an application seeking execution,” says Subramanium. “Most times consumers neglect to file a complaint as they are occupied with their regular work and do not take time to fight the menace against corporate giants; however, the Government has built a consumer-friendly environment and they have called these dispute settlement platforms/Commissions instead of Calling them as Courts (to ensure the Consumer are not deterred with lengthy procedures of regular Courts); At these commissions, summary proceedings will be taking place for expedited justice,” says Makyam. Source: Economic Times

Feeling wronged as a consumer? Know the process and timeline of filing a complaint in a consumer court Read More »

Misleading ads: Public figures must act responsibly while endorsing products, says SC

May 07,2024 It is imperative for celebrities and public figures to act responsibly while endorsing a as advertisers and endorsers are equally responsible for issuing misleading advertisements, the Supreme Court said on Tuesday. Clamping down on misleading advertisements, the apex court directed that before an advertisement is permitted to be issued, a self-declaration be obtained from the advertisers on the line of the Cable Television Networks Rules, 1994. Rule 7 of the 1994 rules deals with advertisement code and stipulates that advertisements carried in the cable service shall be designed to be in conformity with the laws and should not offend morality, decency and religious susceptibilities of the subscribers. “We are of the opinion that advertisers, advertising agencies and endorsers are equally responsible for issuing false and misleading advertisements,” a bench of Justices Hima Kohli and Ahsanuddin Amanullah said. “Endorsements by celebrities, influencers and public figures go a long way in promoting products and it is imperative for them to act with responsibility while endorsing any product in the course of advertisement and taking responsibility for the same…,” the bench observed. The top court said the ministries concerned need to set up a specific procedure which will encourage consumers to lodge complaints regarding misleading advertisements and the complaints be taken to their logical conclusion. It said self-declarations by advertisers shall be uploaded on the ‘Broadcast Seva’ portal which runs under the aegis of the Ministry of Information and Broadcasting Regarding advertisements in the print media, the bench said the ministry shall create a portal within four weeks and advertisers shall file self-declaration before issuing any advertisements. The bench said the proof of filing self-declaration has to be made available by the advertiser to the broadcaster or publisher. It also asked the health ministry to file an affidavit regarding complaints received from 2018 onwards by the Food Safety and Standards Authority of India on misleading advertisements concerning food products and also details of action taken or proposed to be taken on them. The bench referred to the Central Consumer Protection Authority guidelines including those related to children-targeted advertisements and duties of the manufacturer, service provider, advertiser and advertising agency. It also perused the affidavits filed by the ministries of Ayush, consumer affairs and information and broadcasting. Source: Economic Times

Misleading ads: Public figures must act responsibly while endorsing products, says SC Read More »

ICMR to expand its clinical trial network to provide solutions for health issues

Apr 27,2024 New Delhi: The ICMR has planned to expand its Indian Clinical Trial and Education Network (INTENT) and invited tenders from public and private medical research institutes for coordinating regulatory clinical trials for drugs and devices. These expressions of interest would help in the growth of the national network, which encompasses 47 institutes that include public and private medical colleges, hospitals, and research institutes including the ICMR institutes. The ICMR established INTENT, a network of medical colleges and research institutes, with an overarching goal of providing evidence-based, and culturally sensitive solutions to health issues of national priorities by conducting large, decisive, regulation compliant clinical trials. This network is invested in providing an end-to-end solution for clinical trials for the Indian researchers. “The ICMR now plans to expand the national network and accordingly invites expressions of interest (EOI) from public and private medical research institutes in India to contribute to the INTENT activities,” an official document said. The broad objectives of the network are to generate high quality evidence by conducting and coordinating hospital-based and community-based trials in the diseases or health conditions of public health importance in India. The aim is also to guide health policies and informed management practices based on the evidence generated and build capacity of clinical researchers in India for the planning, conduct, analysis and scientific dissemination of the clinical trials, the document stated. The INTENT proposes to co-ordinate regulatory clinical trials or clinical investigations for drugs, devices, vaccines, biologics developed or co-developed with academia, start-ups or industry that address the national health priorities. Additionally, trials that are planned through inter-ministerial collaborations may also be conducted by INTENT. The INTENT is being coordinated by Clinical Studies and Trials Unit (CSTU) under Division of Development Research at ICMR, Delhi. The selected centres from the EOI applicants will have the privilege of first preference as sites in case of trials conducted under the ambit of INTENT. Source: Healthworld

ICMR to expand its clinical trial network to provide solutions for health issues Read More »

Pharmacies raided for selling overpriced meds

Apr 24,2024 Hyderabad: Some medical shops were found to be selling certain anti-fungal medicines at almost double the actual cost, the Drugs Control Administration (DCA) said. Stocks worth 5.5 lakh were seized during two separate raids conducted on Tuesday. DCA officials seized two medicines from shops in Vanasthalipuram and Hayathnagar mandal of Rangareddy district, which were being sold at much higher prices than the central government fixed price. The medicines — Itrazole 100 and Itrazole 200 — are commonly used to treat fungal infections. The drugs were manufactured by Sunfine Health Care in Solan, Himachal Pradesh, and marketed by a company in Haryana. Officials said that Itrazole 200 was being sold at 43 per tablet instead of the actual price of 24 per tablet. Similarly, Itrazole 100 was being sold at 31 per tablet instead of 18, which means a patient has to cough up an extra 100-150 for a strip of ten tablets. “Selling overpriced medicines is not only illegal, but it also means that healthcare is inaccessible to many,” the DCA said, adding that strict action would be taken against offenders. Hyderabad: Some medical shops were found to be selling certain anti-fungal medicines at almost double the actual cost, the Drugs Control Administration (DCA) said. Stocks worth 5.5 lakh were seized during two separate raids conducted on Tuesday. DCA officials seized two medicines from shops in Vanasthalipuram and Hayathnagar mandal of Rangareddy district, which were being sold at much higher prices than the central government fixed price. The medicines — Itrazole 100 and Itrazole 200 — are commonly used to treat fungal infections. The drugs were manufactured by Sunfine Health Care in Solan, Himachal Pradesh, and marketed by a company in Haryana. Officials said that Itrazole 200 was being sold at 43 per tablet instead of the actual price of 24 per tablet. Similarly, Itrazole 100 was being sold at 31 per tablet instead of 18, which means a patient has to cough up an extra 100-150 for a strip of ten tablets. “Selling overpriced medicines is not only illegal, but it also means that healthcare is inaccessible to many,” the DCA said, adding that strict action would be taken against offenders. Source: TOI

Pharmacies raided for selling overpriced meds Read More »

WHO likely to issue wider alert on contaminated J&J cough syrup

Apr 20,2024 London: The World Health Organisation is likely to issue a wider warning about contaminated Johnson and Johnson-made children’s cough syrup found in Nigeria last week, it said in an email. Nigeria’s regulator recalled a batch of Benylin paediatric syrup last Wednesday, having found a high level of diethylene glycol in the product during routine testing. The contaminant, alongside another closely related toxin, ethylene glycol, has been linked to the deaths of more than 300 children in Cameroon, Gambia, Indonesia and Uzbekistan since 2022, though there is no evidence that these incidents are linked with the latest recalls. The U.N. health body said it puts out global medical product alerts to “encourage diligence” by national authorities and was likely to do so in this instance, “subject to confirmation of certain details from parties”. The recalled batch of Benylin syrup was made by J&J in South Africa in May 2021, although Kenvue now owns the brand after a spin-off from J&J last year. J&J has referred requests for comment to Kenvue. In an emailed statement on Friday, Kenvue said it had carried out tests on the batch recalled by Nigeria and had not detected either diethylene or ethylene glycol. “We continue to work closely with health authorities and the WHO and are engaging with NAFDAC to understand their test results, including verifying the authenticity of the sampled product, the testing methodology used, and results reported by the agency,” the statement added. Since Nigeria’s recall, five other African countries have also pulled the product from shelves – Kenya, Rwanda, Tanzania, Zimbabwe and South Africa, where the drug was made. South Africa’s regulator has also recalled another batch of the syrup, which is used to treat coughs, hay fever and other allergic reactions in children. Diethylene glycol is toxic to humans when consumed and can result in acute kidney failure, although there have been no reports of harm in the latest incident. In the 2022 cases, the contamination in the syrups came from the raw materials used by manufacturers in India and Indonesia. The WHO said it was collaborating with both the manufacturer and regulatory authority in South Africa to investigate the Benylin paediatric syrup, and had information on the source of the ingredients used. Kenvue has previously said it tested its ingredients before manufacture. The agency said the possibility that the syrup was counterfeit was also “under consideration as part of investigations”. Earlier this week the WHO sent out a separate alert on five batches of contaminated cough syrup ingredients found in Pakistan that appeared to have been falsely labelled as Dow Chemical products. It was the first alert the WHO has sent on excipients – elements of a medicine other than the active pharmaceutical ingredient – rather than finished products, the agency confirmed on Friday. The batches of propylene glycol were contaminated with ethylene glycol. Source: Pharma

WHO likely to issue wider alert on contaminated J&J cough syrup Read More »